Short bowel syndrome is a chronic, severe condition that can cause patients to experience debilitating physical, emotional, and social challenges.¹⁻⁴



PS=parenteral support; SBS=short bowel syndrome.

FOR MANY WITH SBS WHO ARE DEPENDENT ON PS, THEIR BODY HAS THEM

FROM THE NORLD

SBS IS A CHRONIC AND SEVERE CONDITION, CHARACTERIZED BY MALABSORPTION, AND MANY PATIENTS REQUIRE LONG-TERM PS^{1,2,5}

Patients with SBS suffer from irreparable GI damage and functional deficiency of the intestine primarily due to surgical resection^{2,6}



Many patients with SBS have had a large section of their small intestine removed. In some patients, the colon or large intestine may also be removed^{1,2,7}



Patients experience impaired intestinal absorption of macronutrients, micronutrients, electrolytes, and water⁸



Many patients require long-term PS to maintain energy, hydration, clinical status, and survival^{2,7}

According to an independent analysis, patients with SBS spend significant time receiving PS⁶





days per week (range: 3-7 days)

SBS management goals include⁹:

- Decreasing the severity of SBS symptoms
- Minimizing complications associated with SBS
- Reducing long-term PS dependency

GI=gastrointestinal; SBS=short bowel syndrome.

SBS MAY CAUSE PATIENTS TO EXPERIENCE PHYSICAL BURDENS, DIMINISHED SELF-ESTEEM, AND PSYCHOSOCIAL CHALLENGES^{1,3,4}

Patients with SBS live with debilitating physical burdens of their condition^{1,10,11}

- Abdominal pain
- Frequent bowel movements
- Stool incontinence
- Decreased energy levels

The isolation of SBS and its management may have a negative impact on patients' mental health¹⁰

Patients with SBS report a range of emotions associated with their condition¹⁰:

- Shock from initial diagnosis
- Fear and uncertainty about the future
- Anxiety over physical changes or medical interventions



Not a real patient.

Patients may be reluctant to engage in social activities or relationships due to embarrassment and concerns of stigma¹⁰

SBS can restrict the lives of those living with it, as some patients report^{4,6,10}:



Social withdrawal and isolation


87% of patients reported an impact on enjoyable activities



Concerns over intimacy

Patients reported challenges maintaining relationships

Patients may struggle to convey the extent of the impact of SBS on their daily lives¹⁰



- Carol, living with SBS and dependent on PS



Scan to learn more about the true patient experience

Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.

References: 1, Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr. 2014;38(suppl 1):85-135. doi:10.1177/0148607114520994 2. Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. *Clin Nutr.* 2015;34(2):171-180. doi:10.1016/j.clnu.2014.08.017 3. Carlsson E, Bosaeus I, Nordgren S. Quality of life and concerns in patients with short bowel syndrome. *Clin Nutr.* 2003;22(5):445-452. doi:10.1016/s0261-5614(03)00042-6 4. Winkler MF, Smith CE. Clinical, social, and economic impacts of home parenteral nutrition dependence in short bowel syndrome. *JPEN J Parenter Enteral Nutr.* 2014;38(suppl 1):325-375. doi:10.1177/0148607113517717 5. Belcher E, Mercer D, Raphael BP, Salinas CD, Stacy S, Tappenden KA. Management of short-bowel syndrome: a survey of unmet educational needs among healthcare providers. *JPEN J Parenter Enteral Nutr.* 2022;46(8):1839-1846. doi:10.1002/jpen.2388 6. Data on file. Qualitative interviews of patients with short bowel syndrome and healthcare providers identifying the unmet needs in SB5-IF. 7. Iyer K, Diasies JK, Rubio-Tapia A. AGA clinical practice update on management of short bowel syndrome: expert review. *Clin Gastroenterol Hepatol.* 2022;20(10):2185-2194. e2. doi:10.1016/j.cgh.2022.05.032 8. Seetharam P. Rodrigues G. Short bowel syndrome: a review of management options. *Saudi J Gastroenterol.* 2011;17(4):229-235. doi:10.4103/1319-3767.82573 9. Parrish CR, DiBaise JK, Managing the adult program: digital ethnography study report. Trinity, LLC. August 16, 2023. **11**. Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide– analyses from a randomised, placebo-controlled study. *Clin Nutr.* 2013;32(5):713-721. doi:10.1016/j.clnu.2013.03.016



Ironwood* and its three-leaf design are registered trademarks of Ironwood Pharmaceuticals, Inc. ©2024 Ironwood Pharmaceuticals, Inc. All rights reserved. Intended for licensed US healthcare professionals.